Zanamivir - Vaxart/GlaxoSmithKline
Alternative Names: 4-guanidino Neu5Ac2en; Dectova; GG 167; GR 121167; GR-121167X; RelenzaLatest Information Update: 05 Nov 2023
At a glance
- Originator Biota Holdings; Monash University
- Developer GSK
- Class Antivirals; Guanidines; Pyrans; Sialic acids
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 26 Jan 2023 Phase-II clinical trials in Influenza virus infections (In infants, In neonates) in United Kingdom, Spain (IV) (NCT04494412)
- 23 Oct 2020 Phase-II clinical trials in Influenza virus infections (In neonates, In infants) in Poland, Netherlands (IV) (NCT04494412)
- 31 Jul 2020 GlaxoSmithKline plans a phase II pharmacokinetics trial for Influenza virus infections (In infants, In neonates) (IV, infusion) in October 2020 (NCT04494412)